Key Takeaways TEM and GeneCentric developed PurIST to classify PDAC tumors into classical or basal subtypes. The TEM-led study shows PurIST can guide first-line therapy choices in advanced pancreatic cancer. Findings establish TEM's PurIST as a prognostic and predictive biomarker for improving patient survival.Per a report by the Kenner Family Research Fund, pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients ...